The company’s vaccines are designed to induce protection against early transmission and infection, focusing on the mucosal immune response as a first-line defense, which for some pathogens may be essential for the development of an effective prophylactic vaccine.
The team is conducting research to create a prophylactic nasal vaccine
This vaccine will induce immune protection not only in the blood but will also elicit immune defense protection in the nasal and pulmonary mucous membranes and therefore aims to prevent transmission of the virus and infection at a very early stage before it spreads to other organs.
News 
Market Data 
Discover 
